Neugalinâ„¢ 25: Each capsule contains Pregabalin USP 25 mg.
Neugalinâ„¢ 50: Each capsule contains Pregabalin USP 50 mg.
Neugalinâ„¢ 75: Each capsule contains Pregabalin USP 75 mg.
Neugalinâ„¢ XR 82.5: Each extended release tablet contains Pregabalin USP 82.5 mg.
Neugalinâ„¢ XR 165: Each extended release tablet contains Pregabalin USP 165 mg.
Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid (GABA), it does not bind directly to GABA$_{A}$, GABA$_{B}$ and benzodiazepine receptors. Pregabalin selectively binds to the alpha-2delta subunit protein of voltage-gated calcium channels in various regions of central nervous system tissues. Pregabalin oral bioavailability is approximately 90% and it is well absorbed after oral administration.
Route of administration: Oral.
Neuropathic pain:
Postherpetic neuralgia:
Fibromyalgia: *Capsule* - The recommended dose of Pregabalin for fibromyalgia is 300 to 450 mg/day in two divided doses.
Epilepsy: *Capsule* - Initially 150 mg daily in 2 divided doses, increased if necessary after 7 days to 300 mg daily in 2 divided doses, increased further if necessary after 7 days to maximum 600 mg daily in 2 divided doses.
Generalized anxiety disorder: *Capsule* - Initially 150 mg daily in 2 divided doses, increased if necessary after 7 days to 300 mg in 2 divided doses, increased further if necessary after 7 days to maximum 600 mg daily in 2 divided doses.
In cases of Neuropathic pain and Postherpetic neuralgia:
Or as Directed by the Physician.:
With medicine: Interactions may occur with opioids benzodiazepines, barbiturates, ethanol (alcohol), and other drugs that depress the central nervous system.
With food & others: Administration of pregabalin with food has no clinically relevant effect on the total absorption of pregabalin. Avoid consuming alcohol while taking pregabalin, as pregabalin may potentiate the impairment of motor skills and sedating effects of alcohol.
Overdosage:
Overdose of up to 8000 mg has been reported. The most commonly reported adverse events in overdose are somnolence, confusional state, agitation and restlessness.
Pregnancy Category C: It should be used during pregnancy only if the potential benefits justifies the potential risk to the fetus. Breast feeding is not recommended during treatment with Pregabalin.
The safety and efficacy of pregabalin in pediatric patients have not been established.
Abrupt or rapid discontinuation may result in insomnia, nausea, headache, or diarrhea. Concomitant treatment with Pregabalin and a antidiabetic agent may lead to an additive effect on edema and weight gain. For patients with preexisting cardiac conditions, this may increase the risk of heart failure.
Store below 30°C temperature and dry place, protected from light. Keep all medicines out of reach of children.